ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Lilly and AstraZeneca drop BACE inhibitor lanabecestat

by Lisa M. Jarvis
June 17, 2018 | APPEARED IN VOLUME 96, ISSUE 25

 

Eli Lilly & Co. and AstraZeneca are shutting down Phase III studies of the Alzheimer’s treatment lanabecestat. An early look at data from two trials showed the drug was safe but unlikely to slow down the cognitive decline in people with early or mild forms of the disease. In 2014, Lilly had agreed to pay AstraZeneca up to $500 million to codevelop lanabecestat, a small molecule that blocks the activity of BACE, an enzyme that snips down ­amyloid-β. Lanabecestat adds to Lilly’s list of failed Alzheimer’s treatments, which include the internally developed BACE inhibitor LY2886721, the γ-secretase inhibitor semagacestat, and the anti-amyloid-β antibody solanezumab.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment